Quarterly report pursuant to Section 13 or 15(d)

Note 2 - Liquidity and Uncertainties

v3.8.0.1
Note 2 - Liquidity and Uncertainties
3 Months Ended
Mar. 31, 2018
Notes to Financial Statements  
Substantial Doubt about Going Concern [Text Block]
NOTE
2
- LIQUIDITY AND UNCERTAINTIES
    
In accordance with Accounting Standard Codification (“ASC”)
205
-
40,
“Presentation of Financial Statements – Going Concern”, the Company has evaluated whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within
one
year after the date that the consolidated financial statements are issued. Milestone Scientific has incurred operating losses and negative cash flows from operating activities in virtually each year since its inception. The capital raised in
December 2016
and
January 2017
provided Milestone Scientific with working capital to continue to develop its medical devices and obtain regulatory approval for
one
of its
CompuFlo
® Epidural Computer Controlled Anesthesia System (the “
CompuFlo
Epidural System”), as well as to market its dental devices. Milestone Scientific is actively pursuing the generation of positive cash flows from operating activities through an increase in revenue from its dental business worldwide, the generation of revenue from its medical devices and disposables business in the United States (following
June 2017
FDA approval of its
CompuFlo
Epidural System) and worldwide, and a reduction in operating expenses.
 
Management believes that Milestone Scientific will have sufficient cash reserves to meet its anticipated obligations over the next
twelve
months from the filing date of this quarterly report. However, Milestone Scientific will likely need to raise additional capital prior to the expected generation of sustainable positive cash flow from operating activities and
may
also need to raise additional capital to effectively launch its approved Epidural Device and eventually generate positive cash flow from the medical business.
 
The Company is subject to several risks like those of development stage companies, including dependence on key individuals and products, the difficulties inherent in the development of a commercial market, the potential need to obtain additional capital necessary to fund the development of its products, and competition from larger companies and other medical device companies that develop similar or substitute products. The Company's sales performance, selling and marketing expenditures to develop sales performance, as well as the status of each of its new product development programs and the resulting operating income (loss), will significantly impact its cash requirements.